Back to Agenda
IMI Satellite Session: Patient Centricity - What Is It and How Can We Make It Meaningful? A Roundtable Discussion
Session Chair(s)
Pierre Meulien, PhD
Executive Director
Innovative Medicines Initiative (IMI), Belgium
Pierre Meulien, PhD
Executive Director
Innovative Medicines Initiative (IMI), Belgium
Patient centricity has never been so much in the spotlight. Patient insights and patient data play an increasingly established role in the valuation of healthcare offerings once a drug is on the market; but the role and value of an enhanced patient voice during R&D, in particular during clinical development, is yet to be established. This panel session will focus on patient engagement during research & clinical development. Panellists will present case studies, lessons learned and examples of best practices. The discussion will aim to demonstrate the value of patient involvement in medicines R&D, and will address the following questions and issues: • What does patient centricity mean to different stakeholders? • Why do we need patients to be engaged at an early stage of medicines development? What are the lessons learned from existing cases? • What are the challenges in early patient involvement? • How should patients be engaged for the impact to be real and meaningful?
Speaker(s)
Panel Discussion
Magda Chlebus, MA
EFPIA - European Federation of Pharmaceutical Industries and Associations, Belgium
Executive Director, Science Policy & Regulatory Affairs
Panel Discussion
Juan Garcia-Burgos, MD, PhD
European Medicines Agency, Netherlands
Head of Public and Stakeholders Engagement Department
Panel Discussion
Magda Gunn, PhD
Innovative Medicines Initiative, Belgium
Scientific Project Manager
Panel Discussion
Florian Klett
Eupati Fellow, Switzerland
Executive Secretariat EULAR
Panel Discussion
Debra L. Michaels, MS
DIA, United States
Associate Director, Scientific Programs
Panel Disussion
Kay Jane Warner
GlaxoSmithKline , United Kingdom
Patient Engagement Lead, Patients in Partnership
Have an account?